Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal pap smears

American Journal of Pathology

Volumn 175, Issue 5, 2009, Pages 1831-1847

  Andersson, Sonia ^a   Sowjanya, Pavani ^b   Wangsa, Darawalee ^a,b   Hjerpe, Anders ^a   Johansson, Bo ^a   Auer, Gert ^a   Gravitt, Patti E ^c   Larsson, Catharina ^a   Wallin, Keng Ling ^a   Ried, Thomas ^b   Heselmeyer Haddad, Kerstin ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; TELOMERASE; TERC ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS;

EID: 73649127605     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090122     Document Type: Article

References (41)

1. World Health Organization: Comprehensive cervical cancer control: a guide to essential practice. Geneva, Switzerland, WHO, 2006, p 3
2. Koss LG: The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989, 261:737-743
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19
4. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079
5. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26 Suppl 10:K29-K41
6. Gravitt PE, Coutlee F, Iftner T, Sellors JW, Quint WG, Wheeler CM: New technologies in cervical cancer screening. Vaccine 2008, 26 Suppl 10:K42-K52
7. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001, 92:276-284
8. Norman I, Brismar S, Zhu J, Gaberi V, Hagmar B, Hjerpe A, Andersson S: p16(INK4a) immunocytochemistry in liquid-based cervical cytology: is it feasible for clinical use? Int J Oncol 2007, 31:1339-1343
9. Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G, Ried T: Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1996, 93:479-484
10. Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, Auer G, Ried T: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997, 19:233-240
11. Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005, 166:1229-1238
12. Andersson S, Hansson B, Norman I, Gaberi V, Mints M, Hjerpe A, Karlsen F, Johansson B: Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol 2006, 29:705-711
13. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr., Young N: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119
14. Richart RM: A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol 1990, 75:131-133
15. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM: Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001, 183:1554-1564
16. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38:357-361
17. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM: Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998, 36:3020-3027
18. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B: Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005, 92:2195-2200
19. Moberg M, Gustavsson I, Gyllensten U: Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol 2003, 41:3221-3228
20. Andersson S, Wangsa D, Flores-Staino C, Safari H, Mints M, Hjerpe A, Hagmar B, Johansson B: Expression of p16(INK4a) in relation to histopathology and viral load of 'high-risk' HPV types in cervical neoplastic lesions. Eur J Cancer 2006, 42:2815-2820
21. Linder J, Zahniser D: ThinPrep Papanicolaou testing to reduce false-negative cervical cytology. Arch Pathol Lab Med 1998, 122:139-144
22. Sokolova I, Algeciras-Schimnich A, Song M, Sitailo S, Policht F, Kipp BR, Voss JS, Halling KC, Ruth A, King W, Underwood D, Brainard J, Morrison L: Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diagn 2007, 9:604-611
23. Algeciras-Schimnich A, Policht F, Sitailo S, Song M, Morrison L, Sokolova I: Evaluation of quantity and staining pattern of human papillomavirus (HPV)-infected epithelial cells in thin-layer cervical specimens using optimized HPV-CARD assay. Cancer 2007, 111:330-338
24. Heselmeyer-Haddad K, Janz V, Castle PE, Chaudhri N, White N, Wilber K, Morrison LE, Auer G, Burroughs FH, Sherman ME, Ried T: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 2003, 163:1405-1416
25. Keating JT, Ince T, Crum CP: Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001, 8:83-92
26. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS, Wallin KL: Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004, 10:2407-2414
27. Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K: Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results. Cancer 2007, 111:83-92
28. Duncan L, Jacob S, Hubbard E: Evaluation of p16INK4a as a diagnostic tool in the triage of Pap smears demonstrating atypical squamous cells of undetermined significance. Cancer 2008, 114:34-48
29. Zhang Q, Kuhn L, Denny LA, De Souza M, Taylor S, Wright TC Jr: Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 2007, 120:351-356
30. Masoudi H, Van Niekerk DJ, Gilks CB, Cheang M, Bilek K, Fischer U, Ehlen T, Miller D, Horn LC: Loss of p16 INK4 expression in invasive squamous cell carcinoma of the uterine cervix is an adverse prognostic marker. Histopathology 2006, 49:542-545
31. Caraway NP, Khanna A, Dawlett M, Guo M, Guo N, Lin E, Katz RL: Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol 2008, 110:37-42
32. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000, 2:116-123
33. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, Bryndorf T, Kryger-Baggesen N, Christensen L, Engelholm SA, Philip J: Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999, 24:144-150
34. Hopman AH, Theelen W, Hommelberg PP, Kamps MA, Herrington CS, Morrison LE, Speel EJ, Smedts F, Ramaekers FC: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 2006, 210:412-419
35. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty VV: Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 2004, 4:5
36. Matthews CP, Shera KA, McDougall JK: Genomic changes and HPV type in cervical carcinoma. Proc Soc Exp Biol Med 2000, 223:316-321
37. Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ, Moch H: Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization. Cancer Res 1999, 59:3475-3479
38. Allen DG, White DJ, Hutchins AM, Scurry JP, Tabrizi SN, Garland SM, Armes JE: Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer 2000, 83:1659-1663
39. Umayahara K, Numa F, Suehiro Y, Sakata A, Nawata S, Ogata H, Suminami Y, Sakamoto M, Sasaki K, Kato H: Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer 2002, 33:98-102
40. Hidalgo A, Monroy A, Arana RM, Taja L, Vazquez G, Salcedo M: Chromosomal imbalances in four new uterine cervix carcinoma derived cell lines. BMC Cancer 2003, 3:8
41. Narayan G, Pulido HA, Koul S, Lu XY, Harris CP, Yeh YA, Vargas H, Posso H, Terry MB, Gissmann L, Schneider A, Mansukhani M, Rao PH, Murty VV: Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003, 22:3489-3499